SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 17.16 |
Enterprise Value ($M) | 10.27 |
Book Value ($M) | 12.73 |
Book Value / Share | 0.75 |
Price / Book | 1.35 |
NCAV ($M) | 3.91 |
NCAV / Share | 0.23 |
Price / NCAV | 4.39 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.71 |
Return on Assets (ROA) | -0.77 |
Return on Equity (ROE) | -1.31 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.90 |
Current Ratio | 4.90 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 16.04 |
Assets | 24.86 |
Liabilities | 12.13 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.65 |
Operating Income | -16.89 |
Net Income | -18.40 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -17.49 |
Cash from Investing | -0.53 |
Cash from Financing | 3.47 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Armistice Capital, Llc | 4.99 | 3.01 | |
13G/A | Lind Global Fund II LP | 4.20 | ||
13D | Nantahala Capital Management, LLC | 11.80 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
4,868 | 43,987 | 11.07 | |
29,954 | 130,852 | 22.89 | |
6,275 | 79,757 | 7.87 | |
16,141 | 120,831 | 13.36 | |
(click for more detail) |
Similar Companies | |
---|---|
TBPH – Theravance Biopharma, Inc. | TCRX – TScan Therapeutics, Inc. |
TKNO – Alpha Teknova, Inc. | TNGX – Tango Therapeutics, Inc. |
TRDA – Entrada Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io